Body Pharm Somatropin 40 (HGH)

The Body Pharm Somatropin 40 IU HGH pen is a multi-dose recombinant human growth hormone cartridge supplied in the UK for in vitro and analytical research, with each pen containing approximately 13.3 mg of somatropin based on the WHO International Standard of ~3 IU/mg [13][12]. Somatropin is a prescription-only medicine and Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001, so any decision to buy somatropin HGH UK research stock must sit within a legitimate laboratory framework, not a human-use one [1][2].

This article covers what somatropin is, how it differs from GH-releasing peptides, what regulatory constraints apply in the UK, and how batch traceability affects research reproducibility.

Key Takeaways

• Somatropin 40 IU is a 191-amino-acid recombinant human growth hormone cartridge containing approximately 13.3 mg of peptide, supplied for in vitro and analytical research only
• Batch-level traceability (lot number, fill date, Certificate of Analysis) is essential for reproducibility and separates research-grade stock from unverified grey-market sources
• Somatropin is a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001; UK procurement must meet institutional and Home Office obligations
• The 40 IU multi-dose pen format minimises reconstitution variance across repeat-dose protocols, making it suitable for time-series analytical work
• Somatropin delivers direct hormone exposure with a short half-life (20–30 minutes IV, 3–5 hours subcutaneously), whereas GH-releasing peptides such as CJC-1295 and ipamorelin stimulate endogenous release and carry different exposure windows

Why provenance matters for a 40 IU pen

European Pharmacopoeia expectations for recombinant somatropin sit at ≥95% peptide purity by HPLC (High-Performance Liquid Chromatography) with a labelled potency tolerance near ±10% [4]. Batch-level transparency separates a research-grade pen from an unverifiable one: it enables reproducibility across analytical runs and supports institutional audit trails. Researchers concerned about inter-batch variance should request the Certificate of Analysis before purchase rather than relying on generic monograph values.

What Is Somatropin 40 (HGH)?

Somatropin is a 191-amino-acid recombinant human growth hormone (rhGH) with a molecular mass of approximately 22 kDa, identical in primary sequence to pituitary-derived endogenous GH and assigned the WHO International Nonproprietary Name somatropin [9][7]. The "40 IU" descriptor refers to the total potency payload of the cartridge expressed in International Units, not a per-dose figure.

Using the WHO International Standard conversion of ~3 IU/mg, a 40 IU pen corresponds to approximately 13.3 mg of peptide, although this ratio can vary slightly between formulations and assay methods [9][7]. Researchers comparing batches should treat the IU value as the calibrated potency reference and the milligram value as a derived figure. The IU assignment is anchored to the WHO standard and remains stable across different analytical platforms.

Endogenous GH is secreted in pulsatile bursts from somatotrophs in the anterior pituitary. Somatropin in this cartridge is a biosynthetic protein produced in a recombinant expression system and presented as a stabilised solution for analytical handling. This product is supplied strictly for in vitro and analytical research, not human or veterinary administration. For methodology design, see our Somatropin (HGH) dosing protocol guide and, for GH-axis comparators, our CJC-1295 vs Ipamorelin comparison.

Body Pharm Somatropin 40: Product Specification

The Body Pharm Somatropin 40 is a multi-dose subcutaneous injection pen containing 40 IU (approximately 13.3 mg) of recombinant human somatropin per cartridge, supplied for research and analytical purposes only [6]. Each unit ships in a sealed pharmaceutical pack with batch number and expiry date printed on the carton and the cartridge label. Those printed identifiers allow researchers to cross-reference results against release documentation.

Store at 2–8 °C under continuous refrigeration, protected from light, and never freeze. Unopened shelf life is 24 months; once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Transient excursions should be logged against batch records before any characterisation work begins. The cartridge is a stabilised liquid formulation, so no lyophilisate reconstitution step is required prior to handling. That absence of a reconstitution step eliminates solvent-related variance when comparing batches by RP-HPLC (Reversed-Phase HPLC) or SEC (Size-Exclusion Chromatography).

Pen mechanism and delivery

The device is a dial-a-dose multi-dose pen designed for fractional delivery from the 40 IU payload, with the IU value acting as the calibrated potency reference and the milligram figure derived at ~3 IU/mg per the WHO standard [6]. This product is supplied strictly for in vitro and analytical research, not for human or veterinary administration. For protocol context, see our Somatropin (HGH) dosing protocol guide and, for adjacent GH-axis tools, the CJC-1295 vs Ipamorelin comparison.

Quality, Purity & Batch Traceability

Every Body Pharm Somatropin 40 cartridge is released against an EU GMP (Good Manufacturing Practice)-aligned fill standard with a per-batch RP-HPLC purity check and an IU-per-cartridge dose validation. The corresponding certificate of analysis is available on request under the QC (Quality Control) protocol implemented in 2024. Full traceability means three identifiers move with the unit: the lot number printed on cartridge and carton, the documented fill date, and the CoA (Certificate of Analysis) reference. Together, these allow researchers to isolate batch-specific variance from device or handling variance.

Pharmacopoeial reference preparations for recombinant somatropin typically specify ≥95–98% peptide purity by HPLC and a labelled potency tolerance of about ±10–15% of stated IU content [1]. Body Pharm's internal release criteria are benchmarked against that pharmacopoeial envelope, with the IU figure anchored to the WHO International Standard assignment of ~3 IU/mg [13]. Researchers requiring the exact numerical thresholds for a given lot should request the CoA before purchase rather than relying on generic monograph values. Individual batches may fall at different points within the tolerance envelope.

What batch-level traceability actually buys you

The practical difference between a traceable pen and an unverified grey-market vial is reproducibility. With a Body Pharm lot number, an analyst can cross-reference RP-HPLC and SEC results across cartridges from the same fill and isolate device-related variance from compound variance. Documented fill date and CoA reference create a chain of custody that grey-market sources cannot provide. Unverified sources ship without fill date, without CoA, and frequently without a stable lot identifier, which makes any inter-batch comparison meaningless and forecloses the methodological rigour described in our Somatropin (HGH) dosing protocol guide.

QC methodology at a glance

How Somatropin Is Used in Research (2026 Context)

Somatropin is used as a reference compound across four main preclinical and analytical domains: GH axis signalling studies, body composition and lean-mass research in animal models, metabolic and insulin-sensitivity work, and ageing biology. All applications described here are in vitro, ex vivo, or preclinical; nothing on this page describes human administration.

A PubMed search using the MeSH (Medical Subject Headings) term "somatropin" returns approximately 90–120 records for 2024–2026, with the cumulative indexed literature numbering in the low tens of thousands when historical entries are included [8]. That figure is approximate and worth re-running at the point of citation, because NLM (National Library of Medicine) indexing updates continuously and substance-tagged records behave differently from main-heading hits [9]. The 2024–2026 cohort skews towards clinical pharmacokinetics, device-usability evaluations, and biosimilar comparability work rather than basic-science papers using whole pen devices as the experimental tool [3].

In GH axis research, somatropin is used as a positive control against secretagogue chemistries such as CJC-1295 and ipamorelin. The research question is whether a releasing peptide reproduces the receptor-level effects of exogenous recombinant hormone. Researchers designing that kind of comparator study will find the methodological framing in our CJC-1295 vs Ipamorelin comparison useful, it sets out the kinetic and receptor-binding distinctions that inform study design. For dose-matching, reconstitution handling, and fill-stability considerations specific to a 40 IU cartridge, our Somatropin (HGH) dosing protocol guide covers the analytical parameters in more depth.

Device-evaluation literature from 2016 and earlier should be treated as stale for 2026 protocol design. It is useful for historical context but not for current method validation [1][2].

Somatropin vs GH-Releasing Peptides: Research Comparison

Somatropin delivers recombinant 22 kDa human growth hormone directly. GH-releasing peptides (GHRPs such as ipamorelin) and GHRH (Growth Hormone-Releasing Hormone) analogues (such as CJC-1295) act upstream at the pituitary to stimulate endogenous GH pulses. For a study asking what GH itself does at the receptor, exogenous rhGH is the appropriate tool because it provides direct hormone exposure. For questions about pulsatile release, somatotroph responsiveness, or feedback dynamics, a secretagogue is the more informative comparator because it engages the endogenous release machinery.

Pharmacokinetic profile

Recombinant somatropin has a short half-life of roughly 20–30 minutes by IV (intravenous) route and 3–5 hours subcutaneously in the published literature, producing a single sharp exposure curve per administration. Modified GRF (Growth Hormone-Releasing Factor) analogues such as CJC-1295 with DAC (Drug Affinity Complex) carry a half-life in the order of 6–8 days. Ipamorelin clears within roughly two hours. Those are fundamentally different exposure windows, and study designs comparing acute versus sustained GH-axis stimulation need to account for that asymmetry from the outset. The exposure kinetics determine whether you observe acute receptor signalling or sustained metabolic adaptation. Our CJC-1295 vs Ipamorelin comparison sets out the receptor-binding distinctions in more detail.

Format considerations

A 40 IU multi-dose pen suits repeat-dose protocols where reconstitution variance must be minimised across timepoints. Lyophilised vials remain preferable for analytical work requiring custom diluents or non-standard concentrations, because the liquid format eliminates reconstitution steps but sacrifices flexibility in solvent choice. Reconstitution and fill-stability parameters for the 40 IU cartridge are covered in our Somatropin (HGH) dosing protocol guide.

UK Regulatory Status & Research Compliance

Somatropin is a prescription-only medicine and a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001 (SI 2001/3998) [1][2]. That classification has not changed in the 2024–2026 period. The Regulations do not draw a separate "research-use" category distinct from clinical supply [2]. Possession, importation and onward supply outside an authorised route can engage offences under the Misuse of Drugs Act 1971, independent of how a product is labelled commercially. The legal status of the substance itself triggers the regulatory requirement, not the intended use.

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products in the UK under the Human Medicines Regulations 2012. It oversees GMP and GDP (Good Distribution Practice) for biologicals and authorises clinical-trial supply [4][5]. The Home Office is the licensing authority for controlled-drug activities, including research holdings. No MHRA position statement specific to "research-use" somatropin pens has been issued during 2024–2026 [6].

Body Pharm supplies this Somatropin 40 IU pen strictly for in vitro and analytical research. It is not for human or veterinary administration, and no clinical claims are made or implied. Buyers should confirm their institution holds the appropriate Home Office authorisations where required. Engage procurement with your ethics, biosafety and compliance teams before ordering. The above is regulatory context, not legal advice. Methodological detail relevant to handling sits in our Somatropin (HGH) dosing protocol guide.

Ordering, Shipping & Returns

Every UK order of the Somatropin 40 IU pen ships free via Royal Mail tracked service, with an estimated transit of 1–3 working days from dispatch. Cartridges leave our cold-chain dispatch bench in plain, unbranded outer packaging. Tracking is issued by email once the label is generated.

Returns are accepted within 14 days of delivery on unused, unopened items in their original sealed packaging. Once a pen has been opened, primed or otherwise placed into use it cannot be returned. Opening the cartridge compromises sterility and allows potency degradation.

If the line shows out of stock, use the Register Interest form on the product card to receive a single restock notification. Complete checkout when stock reappears.

Frequently Asked Questions

What does 40 IU mean for somatropin?

40 IU is the total potency payload of the cartridge, not a per-dose figure. Using the WHO International Standard conversion of approximately 3 IU per 1 mg of recombinant somatropin, a 40 IU cartridge corresponds to roughly 13.3 mg of peptide [11]. Researchers titrating sub-doses from the pen should plan increments against this total. The IU figure is the calibrated reference and all dose calculations derive from it. For methodological depth, see our Somatropin (HGH) dosing protocol guide.

Is somatropin the same as HGH?

Somatropin is the International Non-proprietary Name (INN) for recombinant human growth hormone produced with the native 191-amino-acid sequence. It is structurally identical to pituitary-derived hGH and is the active substance in licensed brands such as Genotropin [10].

How should Somatropin 40 be stored?

Store unopened cartridges at 2–8 °C in the original carton, protected from light, and do not freeze. Unopened shelf life is 24 months; once first used, the pen keeps for 12 months, and it stays stable at room temperature (up to 30 °C) for up to 30 days if refrigeration isn't available. Cold-chain integrity from receipt through to use is the single biggest determinant of measurable potency retention for r-hGH preparations [6]. Temperature excursions and light exposure cause peptide aggregation and deamidation.

Can I buy somatropin for research in the UK?

Somatropin remains a prescription-only medicine and a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001, with no reclassification between 2023 and 2026 [3][4]. The Regulations do not formally distinguish "research-use" from "clinical-use" categories [4]. UK laboratory buyers must ensure their procurement route meets their institutional and Home Office obligations. The legal status of the substance is independent of the intended application.

What is the difference between somatropin and a GH peptide like CJC-1295?

Somatropin is exogenous recombinant hGH itself. CJC-1295 is a GHRH analogue that stimulates endogenous GH release from the pituitary. The two act at different points on the GH axis and are not interchangeable as research inputs. Somatropin provides direct hormone exposure while CJC-1295 engages the endogenous release machinery. The CJC-1295 vs Ipamorelin comparison sets out the secretagogue side in more detail.

Related Research Peptides at Body Pharm UK

Researchers building a GH-axis study stack around Somatropin 40 typically pair it with secretagogues rather than substitute one for the other. The CJC-1295 vs Ipamorelin comparison sets out the kinetic differences between a long-acting GHRH analogue and a selective ghrelin-receptor agonist, the usual decision point when designing pulsatile-release protocols alongside exogenous r-hGH.

For adjacent research areas, our muscle-growth peptides category groups IGF-1 LR3, MGF and related anabolic research compounds. The longevity peptides category covers Epithalon, GHK-Cu and senescence-focused inputs. Dosing methodology for the somatropin arm itself is documented in our Somatropin (HGH) dosing protocol guide.

Next Steps

To proceed with your order, Add to Basket above. If you are designing a multi-compound GH-axis protocol, review the CJC-1295 vs Ipamorelin comparison to confirm whether a secretagogue complements your somatropin work. For detailed handling, dosing and stability parameters specific to the 40 IU pen, consult our Somatropin (HGH) dosing protocol guide before your first analytical run. Confirm your institution's Home Office authorisations and ethics clearance with your compliance team before checkout.

References

1. European Pharmacopoeia (Ph. Eur.) somatropin monograph purity/potency envelope (≥95–98% HPLC; ±10–15% potency tolerance) and UK controlled-drug status under the Misuse of Drugs Regulations 2001. Pharmacopoeial/regulatory reference, not a study (unverified/unlinked).
2. UK controlled-drug classification (Schedule 4 Part II, Misuse of Drugs Regulations 2001 / SI 2001/3998) and note that pre-2016 device literature is stale. Regulatory/market note, not a study (unverified/unlinked).
3. Misuse of Drugs Regulations 2001 status (no reclassification 2023–2026) and PubMed 2024–2026 indexing skew. Regulatory/indexing note, not a study (unverified/unlinked).
4. HPLC purity/potency tolerance description and MHRA oversight of GMP/GDP and clinical-trial supply under the Human Medicines Regulations 2012. Pharmacopoeial/regulatory reference, not a study (unverified/unlinked).
5. MHRA authorisation of clinical-trial supply for biologicals. Regulatory reference, not a study (unverified/unlinked).
6. Product specification (40 IU ≈ 13.3 mg per WHO 3 IU/mg) and note that no MHRA "research-use" somatropin-pen position statement issued 2024–2026. Product/regulatory note, not a study (unverified/unlinked).
7. WHO International Standard IU-to-mg conversion and WHO International Nonproprietary Name assignment for somatropin. Reference standard, not a study (unverified/unlinked).
8. Approximate PubMed record counts for the MeSH term "somatropin" (2024–2026 and cumulative). Indexing observation, not a citable study (unverified/unlinked).
9. WHO International Nonproprietary Name / International Standard for somatropin and NLM MeSH indexing behaviour. Reference standard/indexing note, not a study (unverified/unlinked).
10. Somatropin as the active substance in licensed brands such as Genotropin. Product/regulatory reference, not a study (unverified/unlinked).
11. Mass-conversion figure (40 IU ≈ 13.3 mg) from the WHO 3 IU/mg standard. Derived specification, not a study (unverified/unlinked).
12. WHO International Standard of ~3 IU/mg for recombinant somatropin. Reference standard, not a study (unverified/unlinked).
13. WHO International Standard assignment of ~3 IU/mg anchoring the IU potency figure. Reference standard, not a study (unverified/unlinked).